Table 2. Factors associated with tumour regression ⩾50%, including complete tumour regression after six cycles of primary chemotherapy among 125 patients: univariate analysis.

				Univariate model
Variables (total)	Total	No.a		ORb	95% CIc	P
Age (years)
⩽55	65	32
>55	60	23		0.64	0.30–1.39	0.220
Clinical tumour size
>40 mm	55	17
⩽40 mm	69	37		2.58	1.16–5.83	0.011
Histologic SBR grade
Grade 1	25	9
Grade 2	71	29		1.23	0.43–3.51	0.67
Grade 3	29	17		2.52	0.73–8.85	0.09
ER
⩾10%	82	26
<10%	41	27		4.15	1.75–9.99	<10−3
PR
⩾10%	71	27
<10%	50	25		1.63	0.73–3.63	0.190
Her2-neud
Negative	102	41
Positive	20	11		1.82	0.63–5.30	0.221
Ki-67
⩽40%	97	36
>40%	27	18		3.39	1.27–9.21	0.006
Ki-S7
⩽15%	68	22
>15%	57	33		2.88	1.3–6.4	0.004
P53
0	89	36
⩾1%	34	17		1.47	0.62–3.51	0.339

^a#:number of patients with tumour regression ⩾50%, including complete tumour regression after six cycles of primary chemotherapy.

^bOR=odd ratios.

^c95CI=95% confidence interval.

^dHer2-neu positive cases were those with 10% or more positive tumour cells with a moderate or strong intensity of staining, Her2-neu negative cases were all the other cases.